News Headlines Article

Genentech targets blinding disease in new late-stage trials
San Francisco Business Times

Targeting a blinding disease with no known treatment, Genentech Inc. is taking an experimental drug into late-stage trials aimed at slowing progression of the disease and discovering if patients with a specific mutation will benefit more.

Each of the two trials of Genentech’s lampalizumab will enroll about 936 patients with geographic atrophy, the advanced form of age-related macular degeneration, or AMD, South San Francisco-based Genentech said Monday.